Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering

Together with cash on hand, the fully leveraged facility extends Aptevo's funding runway into 2029, enabling achievement of key clinical and preclinical milestones

100% of patients in Cohorts 1-3 remain free of cytokine release syndrome

CRIS-7-derived CD3 design underpins a controlled T-cell response, supporting the differentiated safety profile, combinability with standard of care